argenex (ARGX) to Release Earnings on Thursday

argenex (NASDAQ:ARGX) will likely be issuing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $6.05 per share and revenue of $1.3048 billion for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

argenex Trading Up 1.7%

Shares of NASDAQ ARGX opened at $840.28 on Wednesday. The firm has a fifty day simple moving average of $830.51 and a two-hundred day simple moving average of $810.08. argenex has a 12 month low of $510.05 and a 12 month high of $934.62. The firm has a market capitalization of $52.00 billion, a PE ratio of 36.08, a price-to-earnings-growth ratio of 0.71 and a beta of 0.37.

Analyst Ratings Changes

A number of research firms recently issued reports on ARGX. DZ Bank raised shares of argenex to a “strong-buy” rating in a research note on Friday, December 19th. HC Wainwright boosted their target price on argenex from $774.00 to $915.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Citigroup reduced their price objective on shares of argenex from $1,124.00 to $1,091.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Robert W. Baird cut argenex from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 18th. Finally, TD Cowen boosted their price target on argenex from $800.00 to $1,146.00 and gave the company a “buy” rating in a report on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $986.78.

Institutional Trading of argenex

Several hedge funds have recently bought and sold shares of the stock. Sunbelt Securities Inc. purchased a new position in shares of argenex during the third quarter valued at about $36,000. Transamerica Financial Advisors LLC boosted its stake in argenex by 80.9% during the fourth quarter. Transamerica Financial Advisors LLC now owns 85 shares of the company’s stock valued at $71,000 after buying an additional 38 shares during the last quarter. Horizon Investments LLC bought a new position in argenex during the third quarter valued at approximately $78,000. Geneos Wealth Management Inc. grew its holdings in argenex by 550.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after buying an additional 99 shares in the last quarter. Finally, Rakuten Securities Inc. increased its stake in argenex by 113.1% in the 2nd quarter. Rakuten Securities Inc. now owns 130 shares of the company’s stock worth $72,000 after acquiring an additional 69 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.